Cefoperazone-Sulbactam

Revision as of 13:15, 14 April 2015 by Turky Alkathery (talk | contribs)
Jump to navigation Jump to search
Cefoperazone-Sulbactam
Clinical data
AHFS/Drugs.comMicromedex Detailed Consumer Information
MedlinePlusa601206
ATC code
Pharmacokinetic data
ExcretionHepatic
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC25H27N9O8S2
Molar mass645.67 g/mol
3D model (JSmol)
  (verify)


WikiDoc Resources for Cefoperazone-Sulbactam

Articles

Most recent articles on Cefoperazone-Sulbactam

Most cited articles on Cefoperazone-Sulbactam

Review articles on Cefoperazone-Sulbactam

Articles on Cefoperazone-Sulbactam in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Cefoperazone-Sulbactam

Images of Cefoperazone-Sulbactam

Photos of Cefoperazone-Sulbactam

Podcasts & MP3s on Cefoperazone-Sulbactam

Videos on Cefoperazone-Sulbactam

Evidence Based Medicine

Cochrane Collaboration on Cefoperazone-Sulbactam

Bandolier on Cefoperazone-Sulbactam

TRIP on Cefoperazone-Sulbactam

Clinical Trials

Ongoing Trials on Cefoperazone-Sulbactam at Clinical Trials.gov

Trial results on Cefoperazone-Sulbactam

Clinical Trials on Cefoperazone-Sulbactam at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Cefoperazone-Sulbactam

NICE Guidance on Cefoperazone-Sulbactam

NHS PRODIGY Guidance

FDA on Cefoperazone-Sulbactam

CDC on Cefoperazone-Sulbactam

Books

Books on Cefoperazone-Sulbactam

News

Cefoperazone-Sulbactam in the news

Be alerted to news on Cefoperazone-Sulbactam

News trends on Cefoperazone-Sulbactam

Commentary

Blogs on Cefoperazone-Sulbactam

Definitions

Definitions of Cefoperazone-Sulbactam

Patient Resources / Community

Patient resources on Cefoperazone-Sulbactam

Discussion groups on Cefoperazone-Sulbactam

Patient Handouts on Cefoperazone-Sulbactam

Directions to Hospitals Treating Cefoperazone-Sulbactam

Risk calculators and risk factors for Cefoperazone-Sulbactam

Healthcare Provider Resources

Symptoms of Cefoperazone-Sulbactam

Causes & Risk Factors for Cefoperazone-Sulbactam

Diagnostic studies for Cefoperazone-Sulbactam

Treatment of Cefoperazone-Sulbactam

Continuing Medical Education (CME)

CME Programs on Cefoperazone-Sulbactam

International

Cefoperazone-Sulbactam en Espanol

Cefoperazone-Sulbactam en Francais

Business

Cefoperazone-Sulbactam in the Marketplace

Patents on Cefoperazone-Sulbactam

Experimental / Informatics

List of terms related to Cefoperazone-Sulbactam

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Cefoperazone is a third-generation cephalosporin antibiotic, marketed by Pfizer under the name Cefobid, and also marked by Pharco B International under the name Cefazone and also marketed by Sigmatec Pharmaceuticals under the name Cefoperazone. It is one of few cephalosporin antibiotics effective in treating Pseudomonas bacterial infections which are otherwise resistant to these antibiotics. Cefina-SB is a combination of sulbactam and cefoperazone. Cefoperazone exerts its bactericidal effect by inhibiting the bacterial cell wall synthesis, and sulbactam acts as a beta-lactamase inhibitor, to increase the antibacterial activity of cefoperazone against beta-lactamase-producing organisms. In some countries, the combination is sold as Sulperazone. Gepach International markets this combination of cefoperazone with sulbactam under the brand name Bacperazone.In India and SriLanka (Cefoperazone-Sulbactam) is manufacterd by Pfizer under the brand name of Magnex/Magnex-Forte depending on the Cefoperazone-Sulbactam ratio.

Spectrum of bacterial susceptibility

Cefoperazone has a broad spectrum of activity and has been used to target bacteria responsible for causing infections of the respiratory and urinary tract, skin, and the female genital tract. The following represents MIC susceptibility data for a few medically significant microorganisms.

  • Haemophilus influenzae: 0.12 - 0.25 µg/ml
  • Staphylococcus aureus: 0.125 - 32 µg/ml
  • Streptococcus pneumoniae: ≤0.007 - 1 µg/ml

[1] [2]

Adverse effects

Cefoperazone contains an N-methylthiotetrazole (NMTT or 1-MTT) side chain. As the antibiotic is broken down in the body, it releases free NMTT, which can cause hypoprothrombinemia (likely due to inhibition of the enzyme vitamin K epoxide reductase) and a reaction with ethanol similar to that produced by disulfiram (Antabuse), due to inhibition of aldehyde dehydrogenase.[3]

References

  1. http://antibiotics.toku-e.com/antimicrobial_462_1.html
  2. http://www.toku-e.com/Assets/MIC/Cefoperazone%20sodium.pdf
  3. Stork CM (2006). "Antibiotics, antifungals, and antivirals". In Nelson LH, Flomenbaum N, Goldfrank LR, Hoffman RL, Howland MD, Lewin NA (eds.). Goldfrank's toxicologic emergencies. New York: McGraw-Hill. p. 847. ISBN 0-07-143763-0. Retrieved 2009-07-03.